Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.47−0.39 (-1.35%)
Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%
Pfizer revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Pfizer's revenue for the twelve months ending Jun 28, 2026 was $63.70B, down 0.2% year over year. For fiscal 2025 it was $62.58B, down 1.6% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $101.18B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.58B | -1.6% |
| FY2024 | Dec 31, 2024 | $63.63B | +6.8% |
| FY2023 | Dec 31, 2023 | $59.55B | -41.1% |
| FY2022 | Dec 31, 2022 | $101.18B | +24.5% |
| FY2021 | Dec 31, 2021 | $81.29B | +95.2% |
| FY2020 | Dec 31, 2020 | $41.65B | +1.8% |
| FY2019 | Dec 31, 2019 | $40.91B | +0.2% |
| FY2018 | Dec 31, 2018 | $40.83B | -22.3% |
| FY2017 | Dec 31, 2017 | $52.55B | -0.5% |
| FY2016 | Dec 31, 2016 | $52.82B | +8.1% |
| FY2015 | Dec 31, 2015 | $48.85B | -1.5% |
| FY2014 | Dec 31, 2014 | $49.61B | -3.8% |
| FY2013 | Dec 31, 2013 | $51.58B | -5.6% |
| FY2012 | Dec 31, 2012 | $54.66B | -10.4% |
| FY2011 | Dec 31, 2011 | $61.04B | -6.3% |
| FY2010 | Dec 31, 2010 | $65.17B | +32.3% |
| FY2009 | Dec 31, 2009 | $49.27B | +2.0% |
| FY2008 | Dec 31, 2008 | $48.30B | -0.3% |
| FY2007 | Dec 31, 2007 | $48.42B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 28, 2026 | $15.03B | +2.6% |
| Q1 FY2026 | Mar 29, 2026 | $14.45B | +5.4% |
| Q4 FY2025 | Dec 31, 2025 | $17.56B | -1.2% |
| Q3 FY2025 | Sep 28, 2025 | $16.65B | -5.9% |
| Q2 FY2025 | Jun 29, 2025 | $14.65B | +10.3% |
| Q1 FY2025 | Mar 30, 2025 | $13.72B | -7.8% |
| Q4 FY2024 | Dec 31, 2024 | $17.76B | +21.9% |
| Q3 FY2024 | Sep 29, 2024 | $17.70B | +31.2% |
| Q2 FY2024 | Jun 30, 2024 | $13.28B | +2.1% |
| Q1 FY2024 | Mar 31, 2024 | $14.88B | -19.5% |
| Q4 FY2023 | Dec 31, 2023 | $14.57B | -42.0% |
| Q3 FY2023 | Oct 1, 2023 | $13.49B | -40.4% |
| Q2 FY2023 | Jul 2, 2023 | $13.01B | -53.1% |
| Q1 FY2023 | Apr 2, 2023 | $18.49B | -28.0% |
| Q4 FY2022 | Dec 31, 2022 | $25.14B | +5.4% |
| Q3 FY2022 | Oct 2, 2022 | $22.64B | -5.8% |
| Q2 FY2022 | Jul 3, 2022 | $27.74B | +46.8% |
| Q1 FY2022 | Apr 3, 2022 | $25.66B | +76.8% |
| Q4 FY2021 | Dec 31, 2021 | $23.84B | +108.6% |
| Q3 FY2021 | Oct 3, 2021 | $24.04B | +133.9% |
| Q2 FY2021 | Jul 4, 2021 | $18.90B | +91.6% |
| Q1 FY2021 | Apr 4, 2021 | $14.52B | +44.0% |
| Q4 FY2020 | Dec 31, 2020 | $11.43B | +520.0% |
| Q3 FY2020 | Sep 27, 2020 | $10.28B | -19.0% |
| Q2 FY2020 | Jun 28, 2020 | $9.86B | -25.6% |
| Q1 FY2020 | Mar 29, 2020 | $10.08B | -23.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.84B | +59.6% |
| Q3 FY2019 | Sep 29, 2019 | $12.68B | -4.6% |
| Q2 FY2019 | Jun 30, 2019 | $13.26B | -1.5% |
| Q1 FY2019 | Mar 31, 2019 | $13.12B | +1.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.16B | -91.6% |
| Q3 FY2018 | Sep 30, 2018 | $13.30B | +1.0% |
| Q2 FY2018 | Jul 1, 2018 | $13.47B | +4.4% |
| Q1 FY2018 | Apr 1, 2018 | $12.91B | +1.0% |
| Q4 FY2017 | Dec 31, 2017 | $13.70B | +0.6% |
| Q3 FY2017 | Oct 1, 2017 | $13.17B | +0.9% |
| Q2 FY2017 | Jul 2, 2017 | $12.90B | – |
| Q1 FY2017 | Apr 2, 2017 | $12.78B | – |
| Q4 FY2016 | Dec 31, 2016 | $13.63B | – |
| Q3 FY2016 | Oct 2, 2016 | $13.05B | – |
See a number that looks wrong?